Herbs (Global Traditional) · Amazonian
Guazuma ulmifolia
Moderate Evidencebotanical
Hermetica Superfood Encyclopedia
Guazuma ulmifolia is an Amazonian tree whose bark contains bioactive flavonoids and triterpenoids that regulate glucose metabolism and reduce inflammation. Clinical studies demonstrate significant blood sugar reduction in Type 2 diabetes patients, with additional gastroprotective effects shown in preclinical research.
Guazuma ulmifolia is a tropical tree native to Central and South America belonging to the Malvaceae family. The plant's stem bark, leaves, and flowers are processed into aqueous extracts (teas), ethanolic extracts, or dried powders containing polyphenols and procyanidins with antioxidant properties.
The strongest evidence comes from a randomized, double-blind, placebo-controlled trial (NCT03313856) with 40 Type 2 diabetes patients showing significant improvements in HbA1c (9.9% to 8.9%, P=.002) and fasting glucose after 90 days. Laboratory studies demonstrate gastroprotective effects equivalent to omeprazole and cardioprotective properties against doxorubicin toxicity, though human trials for these indications are lacking.
Clinical trial dosage: 400 mg of Guazuma ulmifolia/Tecoma stans herbarium mixture before each meal (1,200 mg daily) for diabetes management. Traditional preparations include aqueous teas from stem bark, leaves, or flowers. No standardized extract concentrations have been established. Consult a healthcare provider before starting any new supplement.
Guazuma ulmifolia (commonly known as mutamba or West Indian elm) bark, leaves, and fruit contain a diverse array of bioactive compounds. **Polyphenols & Tannins:** Rich in proanthocyanidins (condensed tannins, ~8–15% dry weight in bark), catechins, epicatechin, and procyanidins — these are the primary compounds linked to its antidiabetic and gastroprotective effects. **Flavonoids:** Contains kaempferol, quercetin, and tiliroside; leaf extracts may yield flavonoid concentrations of ~2–5 mg/g dry weight. **Alkaloids & Terpenoids:** Caffeine has been detected in trace amounts in some preparations; triterpene saponins and lupeol are present in bark. **Mucilage & Fiber:** The fruit pulp is notably mucilaginous with soluble dietary fiber (~12–18% dry weight), which contributes to its traditional use as a digestive aid and may slow glucose absorption. **Fatty acids:** Seeds contain approximately 10–15% oil, predominantly oleic acid (~45%), palmitic acid (~25%), and linoleic acid (~20%). **Minerals:** Leaf and bark preparations provide moderate amounts of calcium (~150–300 mg/100g dry weight), potassium (~400–600 mg/100g), magnesium (~80–150 mg/100g), iron (~5–12 mg/100g), and zinc (~2–4 mg/100g), though exact values vary by plant part and soil conditions. **Protein:** Leaves contain roughly 10–16% crude protein (dry weight); fruit pulp is lower at ~5–8%. **Vitamins:** Limited data, but some ascorbic acid (~15–30 mg/100g fresh fruit pulp) and traces of B-vitamins have been reported. **Key bioactive compound — Procyanidin B2:** Identified as a major active constituent in bark extracts responsible for α-glucosidase inhibition (IC50 values in the low μM range), directly relevant to its blood sugar–lowering activity. **Bioavailability notes:** Condensed tannins and proanthocyanidins generally have low oral bioavailability (estimated <5–10% absorption), but they exert significant local effects in the gastrointestinal tract (relevant to gastroprotection and glucose absorption modulation). Mucilage may further modulate absorption kinetics of co-ingested compounds. Traditional preparation as a decoction (boiled bark/leaf tea) enhances extraction of water-soluble polyphenols and tannins compared to cold infusion.
Guazuma ulmifolia's flavonoids, particularly quercetin and kaempferol derivatives, enhance glucose uptake by activating GLUT4 transporters and improving insulin sensitivity. The plant's triterpenoids inhibit cyclooxygenase-2 (COX-2) and reduce pro-inflammatory cytokines like TNF-α and IL-6. These compounds also stimulate prostaglandin E2 production, which protects gastric mucosa from NSAID-induced damage.
A randomized controlled trial with 40 Type 2 diabetes patients showed Guazuma ulmifolia bark extract significantly reduced fasting blood glucose and HbA1c levels over 12 weeks. Animal studies demonstrated gastroprotective effects comparable to omeprazole against NSAID-induced ulcers. However, human clinical evidence remains limited to the single diabetes study. Larger, longer-term trials are needed to establish optimal dosing and confirm safety profiles.
Guazuma ulmifolia may cause hypoglycemia when combined with diabetes medications, requiring blood sugar monitoring and potential dose adjustments. No serious adverse effects were reported in the clinical trial, though mild gastrointestinal upset may occur. Pregnant and breastfeeding women should avoid use due to insufficient safety data. The herb may interact with anticoagulant medications due to its flavonoid content.
